Cardiovascular prevention by dietary nitrate and nitrite.

OVER THE PAST HALF CENTURY, dietary nitrate (NO3 ) and nitrite (NO2 ) have become notorious because of their proposed association with the development of disease, most notably gastric cancer (28, 38). This has led to very strict regulations of nitrate and nitrite levels in food and drinking water. In the early 1980s, it was surprisingly shown that, in addition to dietary exposure, nitrate and nitrite are also generated endogenously in our bodies (9). Soon after this, the entire L-arginine-nitric oxide (NO) pathway was revealed, and this pathway was found to be the major source of endogenous nitrate and nitrite, since NO is quickly oxidized to these higher nitrogen oxides (11, 30, 37). Until only recently biologists have considered nitrate and nitrite merely as inactive end-products of NO metabolism, but this view is now changing rapidly. It turns out that they undergo a serial reduction in vivo and again form bioactive nitrogen oxides, including NO (7, 24–26, 42, 44). A picture is now emerging suggesting important physiological as well as therapeutical roles for the nitrate-nitrite-NO pathway, especially under hypoxic conditions when oxygen-dependent NO synthases (NOSs) may be dysfunctional (26). Thus, instead of just wasting oxidized NO, our bodies are actively recycling it. Nitrite reduction to NO was first described in the stomach, where salivary nitrite forms NO nonenzymatically via acidcatalyzed reduction (2, 27). Soon after this, Zweier et al. (45) described NOS-independent nitrite reduction in the ischemic and acidic heart. Subsequent studies have shown that a variety of enzymes and proteins can catalyze the one-electron reduction of nitrite to NO in blood and tissues. These include deoxygenated heme proteins (4, 31), xanthine oxidase (43), and components of the mitochondrial respiratory chain (19). In addition, reducing agents such as vitamin C (29) and polyphenols (6) greatly accelerate nitrite reduction. The therapeutic effects of nitrite have been elucidated in the cardiovascular system and in the gastrointestinal tract (26). Systemic delivery of nitrite at remarkably low doses has been shown to protect against ischemia-reperfusion injury in various organs, including the heart (5, 40), brain (17), kidney (39), liver (5), and limb (20). Both nitrate and nitrite are also active when given orally. Nitrate is first reduced by oral commensal bacteria (8) or by mammalian enzymes (13) to form nitrite, which then can enter the systemic circulation (23). In humans, blood pressure is reduced after the ingestion of nitrate in doses equivalent to a diet rich in vegetables (21). Moreover, dietary nitrate also prevents endothelial dysfunction after an acute ischemic insult in humans and inhibits ex vivo platelet aggregation (41). In animal studies, dietary nitrate (3) and nitrite (3, 34) protect against ischemia-reperfusion injury. Jansson et al. (14) and Petersson et al. (32) recently described anti-inflammatory effects of dietary nitrate and nitrite in the gastrointestinal tract, but until today, there have been no reports on the effects of nitrate or nitrite on vascular inflammation. In this issue of the American Journal of Physiology-Heart and Circulatory Physiology, Stokes and colleagues (36) studied the effects of dietary nitrite supplementation on the vascular events associated with a high-cholesterol diet. Mice fed a cholesterol-enriched diet for 3 wk developed clear signs of vascular pathology, including elevated leukocyte adhesion and emigration as well as impaired endothelium-dependent vasorelaxation. Remarkably, the addition of nitrite to drinking water prevented these events. This might be of significant importance since inflammatory events are thought to be central in the development of atherosclerosis. The exact mechanism for these beneficial effects remains to be studied, although the reduction of nitrite to NO and other closely related nitrogen oxides (e.g., S-nitrosothiols) is a likely first step. Indeed, NO has antiinflammatory, antiadhesive, and vasodilatory properties, and reduced NO bioavailability is a central even in the development of cardiovascular disease, including atherosclerosis and hypertension (12). Interestingly, Stokes and colleagues noted a sparing of reduced tetrahydrobiopterin with nitrite treatment. This cofactor is vital for NO generation by NOS, which would indicate that nitrite can function not only as a direct substrate for NO generation but, in addition, might also enhance NO generation from the classical NOS pathway and prevent potentially harmful uncoupling of NOS. Stokes and colleagues also found that the levels of C-reactive protein (CRP) were lower in cholesterol-fed mice treated with nitrite. This is very interesting, especially in light of recent studies in humans showing that this marker of vascular inflammation is coupled to clinical outcome (33, 35). In addition, there might be a direct link to the NO system, since CRP has been shown to induce endothelial dysfunction and uncoupling of endothelial NOS in vivo (10). In a recent large-scale clinical study (33), apparently healthy subjects with increased highsensitivity CRP but without hyperlipidemia were treated with a statin. The treatment was associated with a reduction in CRP and a markedly reduced risk for major cardiovascular events. Although this does not prove a causal link between CRP and cardiovascular events, it indicates that suppression of chronic vascular inflammation has long-term beneficial effects. Surprisingly, there was no effect of nitrite on blood pressure in the present study, despite a great increase in circulating and tissue levels of nitrite and nitroso species. In humans and rats, even a modest increase in plasma nitrite (induced by ingestion of nitrate) is associated with a significant blood pressure reduction (21, 32, 41). The reason for this difference is not clear, but we cannot exclude that nitrate and nitrite have different pharmacodynamic profiles. However, a more likely explanation for these diverging results is related to technical issues. Stokes and colleagues measured blood pressure in anesthetized animals, whereas Larsen et al. measured in awake subjects and Petersen et al. used telemetric measurements in Address for reprint requests and other correspondence: J. O. Lundberg, Dept. of Physiology and Pharmacology, Karolinska Institutet, Stockholm S-171 77, Sweden (e-mail: [email protected]). Am J Physiol Heart Circ Physiol 296: H1221–H1223, 2009; doi:10.1152/ajpheart.00246.2009.